Endovia Health Sciences (EDVA) Cash & Equivalents Growth (1y) (2012 - 2026)
Powered by 
Analysis
Endovia Health Sciences (EDVA) Cash & Equivalents Growth (1y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.50 Bn | 133.65 Bn | 2.84 Bn | 23.56% |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 23.05% |
| 3 | Argenx Se | 65.05 Bn | 59.86 Bn | 1.37 Bn | 71.81% |
| 4 | Moderna | 57.11 Bn | 51.98 Bn | 52.00 Mn | 34.71% |
| 5 | Revolution Medicines | 44.71 Bn | 44.71 Bn | - | - |
| 6 | BeOne Medicines | 40.40 Bn | 35.31 Bn | 1.53 Bn | 84.98% |
| 7 | Alnylam Pharmaceuticals | 35.36 Bn | 32.05 Bn | 992.69 Mn | 53.39% |
| 8 | Royalty Pharma | 28.16 Bn | 27.32 Bn | - | 28.50% |
| 9 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | -57.58% |
| 10 | Endovia Health Sciences | 801,166.21 | 558,464.21 | - | 1,309.99% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,309.99% |
| Dec 31, 2025 | 1,941.01% |
| Sep 30, 2025 | -41.85% |
| Jun 30, 2025 | 107.44% |
| Dec 31, 2024 | -96.37% |
| Sep 30, 2024 | 375.33% |
| Jun 30, 2024 | -99.08% |
| Mar 31, 2024 | -99.31% |
| Dec 31, 2023 | -91.43% |
| Sep 30, 2023 | -96.30% |
| Jun 30, 2023 | -78.53% |
| Mar 31, 2023 | -74.74% |
| Dec 31, 2022 | 5.99% |
| Sep 30, 2022 | -68.06% |
| Jun 30, 2022 | -64.78% |
| Mar 31, 2022 | 593.30% |
| Dec 31, 2021 | 1,000.36% |
| Sep 30, 2021 | 979.23% |
| Jun 30, 2021 | 9,957.81% |
| Mar 31, 2021 | 97.64% |